Antibody-based therapy of COVID-19: How, when, and who to treat? (6)

Professor Koopmans, What do we know about the antibody-based therapeutic approaches to treat COVID-19 Coronavirus? Dr. Anton Titov, MD. Some antibodies were developed against the source. This is 80% similarity in genetic sequence to the COVID-19 Coronavirus. Medical second opinion is important. They are related. There were reports that that antibody could be active. That was research coming out of the Netherlands. The monoclonal antibody therapy is one of the ways that is actively being investigated because it can be done relatively fast. It is one of the means of potentially treating patients. The model for that comes from for the Ebola outbreak, where monoclonal antibodies for the first time have been tested in the field. There is now some preliminary data that show that that that that works. Medical second opinion is important. This is very Much pushed. But we have to be careful. We are not sure that that is going to work because one practical problem is that you would need to test patients early on, before they get very sick. By the time they are in the ICU. That is probably too late. Medical second opinion is important. That means we also need to understand who to treat. That combination is is still complicated. But it is up Yeah, very actively being explored.